tirzepatide allodynia Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System GLP-1 Drugs: New Reports of

Psychoneuroendocrinology 38:1259-1270

165 The S-NO-AAT expresses a potent antimicrobial activity, inhibits cysteine proteases, and induces heme oxygenase-1 expression in hepatic ischemia-reperfusion injury in rats

Clinical trial data suggests tirzepatide produces greater average weight loss than semaglutide, largely because it activates both the GLP-1 and GIP receptors rather than just GLP-1

Relief Sought: General damages, wrongful death damages, loss of consortium, punitive damages Verdict: The jury awarded $253 million to Carol Ernst

End of life of fuel cells and hydrogen products: from technologies to strategies

Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study